苯磺酸氨氯地平与厄贝沙坦治疗老年原发性高血压的成本-效果分析

摘要/Abstract

摘要： 目的分析厄贝沙坦与苯磺酸氨氯地平治疗老年原发性高血压的成本-效果。方法纳入2023年9月—2024年7月茂县妇幼保健院收治的70例原发性高血压老年患者为研究对象,通过随机数表法将患者分为两组,每组35例,分别予以苯磺酸氨氯地平以及厄贝沙坦口服治疗。比较两组治疗效果、治疗前后血压改变情况、治疗成本及不良反应发生情况。结果苯磺酸氨氯地平组总有效率与厄贝沙坦组比较,差异无统计学意义（P>0.05）;治疗8周后,两组收缩压、舒张压、平均动脉压均低于治疗前,且苯磺酸氨氯地平组低于厄贝沙坦组,差异均具有统计学意义（P<0.05）;苯磺酸氨氯地平组直接成本、日均费用均低于厄贝沙坦组,差异均具有统计学意义（P<0.05）;苯磺酸氨氯地平组的成本效益比（C/E）优于厄贝沙坦组,差异具有统计学意义（P<0.05）;苯磺酸氨氯地平组不良反应总发生率与厄贝沙坦组比较,差异无统计学意义（P>0.05）。结论苯磺酸氨氯地平在治疗老年原发性高血压方面与厄贝沙坦具有相似的治疗效果,且安全性较好,但在降低血压、减少治疗成本和提高成本效果比方面表现更优。

关键词: 苯磺酸氨氯地平, 厄贝沙坦, 老年原发性高血压, 成本-效果

Abstract: Objective To analyze the cost-effectiveness of irbesartan and amlodipine besylate in the treatment of essential hypertension in the elderly. Methods A total of 70 elderly patients with essential hypertension admitted to our hospital between September 2023 and July 2024 were included in this study.The patients were divided into two groups by the random number table method, with 35 people in each group, who were given oral treatment of amlodipine besylate and irbesartan respectively.The treatment effect, blood pressure changes before and after treatment, treatment cost and the occurrence of adverse effects were compared between the two groups. Results Amlodipine benzlate group was compared with irbesartan group (P>0.05). After 8 weeks of treatment, systolic, diastolic and mean arterial pressure in both groups were lower than before treatment, and amlodipine benzene late group was lower than irbesartan group (P<0.05). The direct cost of amlodipine group and average daily cost were lower than RMB (P<0.05). The C/E in the amlodipine benzlate group was better than that in the irbesartan group. The overall incidence of adverse effects in the amlodipine phenlate group and irbesartan group(P>0.05). Conclusion Amlodipine benzene late has similar therapeutic effect to irbesartan in treating essential hypertension in the elderly, but better performance in reducing blood pressure, reducing treatment cost and improving cost-effectiveness ratio.

Key words: amlodipine phenylate, irbesartan, essential hypertension in the elderly, cost-effectiveness

中图分类号:

R544.1

孙运慧. 苯磺酸氨氯地平与厄贝沙坦治疗老年原发性高血压的成本-效果分析[J]. 中华养生保健, 2025, 43(8): 177-180.

SUN Yun-hui. Cost-Effectiveness Analysis of Amlodipine Benzene Late Versus Irbesartan for Essential Hypertension in the Elderly[J]. ZHONGHUA YANGSHENG BAOJIAN, 2025, 43(8): 177-180.

参考文献

[1] RAKUGI H, KARIO K, YAMAGUCHI M, et al.Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study[J]. Hypertens Res,2022,45(5):824-833.
[2] HARPER G M. Three Decades of Progress Since the Systolic Hypertension in the Elderly Program[J]. Clin Geriatr Med,2024 ,40(4):xiii-xiv.
[3] 曾广玲. 苯磺酸氨氯地平片联合厄贝沙坦片治疗原发性高血压的临床疗效[J].中国科技期刊数据库医药,2024,10:93-96.
[4] 梁岩. 厄贝沙坦氢氯噻嗪与苯磺酸氨氯地平治疗老年高血压的效果对比评价[J].中文科技期刊数据库(文摘版)医药卫生,2024,3:9-12.
[5] 中国老年学学会心脑血管病专业委员会,中国意识协会循证医学专业委员会.老年高血压的诊断与治疗中国专家共识(2011版)[J].中国心血管病研究,2011,9(11):801-808.
[6] 陈杰. 苯磺酸氨氯地平片联合厄贝沙坦氢氯噻嗪片治疗老年高血压的临床效果[J].中国社区医师,2024,40(8):10-12.
[7] 潘福祥. 厄贝沙坦氢氯噻嗪与苯磺酸氨氯地平治疗老年原发性高血压对患者血压及血压变异性的影响比较[J].心血管病防治知识(学术版),2024,14(3):14-16.
[8] 李一. 厄贝沙坦联合苯磺酸左旋氨氯地平治疗老年原发性高血压的临床分析[J].中文科技期刊数据库(引文版)医药卫生,2024,10:5-9.
[9] 张海,林菁红,苏东风.氢氯噻嗪与厄贝沙坦联合苯磺酸氨氯地平治疗原发性高血压病效果及成本-效果的对比分析[J].临床合理用药杂志,2023,16(27):70-72,76.
[10] 刁微微. 厄贝沙坦和苯磺酸左旋氨氯地平在治疗初诊老年性单纯收缩期高血压的临床比较[J].国际医药研究前沿,2022,6(5):59-62.
[11] 汤雅惠,肖基达.厄贝沙坦氢氯噻嗪片仿制药与原研药治疗轻中度原发性高血压的成本-效果比较[J].中国现代药物应用,2024,18(7):73-77.
[12] 李国妹. 厄贝沙坦联合苯磺酸左旋氨氯地平治疗老年原发性高血压的疗效分析[J].中文科技期刊数据库(引文版)医药卫生,2023,11:109-112.
[13] 韩娟. 四种抗高血压药物的成本-效果分析[J].中国实用医药,2021,16(20):155-157.
[14] 张丽琼,田源,耿兴星.带量集中采购前后氨氯地平和厄贝沙坦治疗原发性高血压的经济性对比[J].中国药物经济学,2023,18(5):43-46,51.
[15] 李惠莹. 海南地区国家组织药品带量采购下原发性高血压3种治疗方案的药物经济学研究[J].中国卫生产业,2022,19(2):146-148,152
[16] 徐琳琳,刘芬,白荣珊.高血压患者服药依从性现状分析及护理干预对策研究[J].科技与健康,2023,2(6):106-108
[17] 包艳琼. 氢氯噻嗪+厄贝沙坦治疗老年原发性高血压的临床疗效及有效率分析[J].中文科技期刊数据库(全文版)医药卫生,2024,4:62-65.